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Context: The GnRH receptor plays a central role in regulating go-
nadotropin synthesis and release, and several mutations in the
GNRHR gene have been reported in patients with idiopathic or fa-
milial forms of isolated hypogonadotropic hypogonadism (IHH).
Objective: The objective of the study was to investigate whether
partial loss-of-function mutations in the GnRH receptor might be
responsible for delayed puberty phenotypes.
Patients: Patients included sibling pairs with delayed puberty (n 
8) or those in whom one brother had delayed puberty and another had
hypogonadotropic hypogonadism (n  3).
Methods:Methods included mutational analysis of the GNRHR gene.
Results:Ahomozygous R262Qmutation in the GnRH receptor was
identified in two brothers from one family. In this kindred, the
proband presented at 15 yr of age with delayed puberty. After a
short course of testosterone, he seemed to be progressing through
puberty appropriately and was discharged from follow-up. His
younger brother was also referred with delayed puberty but showed
little progress after treatment. Frequent sampling revealed de-
tectable but apulsatile LH and FSH release. His clinical progress
was consistent with IHH, and he requires ongoing testosterone
replacement.
Conclusions: Homozygous partial loss-of-function mutations in the
GnRH receptor, such as R262Q, can presentwith variable phenotypes
including apparent delayed puberty. Ongoing clinical vigilancemight
be required when patients are discharged from follow-up, especially
when there is a family history of delayed puberty or IHH because
oligospermia and reduced bone mineralization can occur with time.
(J Clin Endocrinol Metab 91: 5117–5121, 2006)
CONSTITUTIONAL DELAY OF growth and puberty(CDGP) is one of themost frequent reasons for referral
to the pediatric/adolescent endocrinology clinic. In most
situations puberty will occur normally, albeit at a later age,
but in a small proportion of cases, delayed puberty may
reflect a more significant underlying endocrine condition,
such as hypogonadotropic hypogonadism or panhypopitu-
itarism (1).
Differentiating these rare but serious conditions from
more prevalent and benign conditions such as CDGP can be
difficult. A short course of low-dose sex steroids is often
useful to induce early secondary sexual characteristics and to
stimulate endogenous puberty. A diagnosis of CDGP can
usually be made if puberty continues to progress normally
after this treatment, and the young adult can be discharged
from further follow-up and avoid unnecessary medicaliza-
tion. However, failure to progress naturally in puberty, or to
obtain an appropriate growth spurt,may suggest that further
investigations or full pubertal induction are necessary.
In the past decade, several monogenic causes of hypogo-
nadotropic hypogonadism have been identified. Some of
these conditions have associated features such as hyposmia
or abnormal neuronal migration (KAL, FGFR1, NELF), obe-
sity (leptin, leptin receptor, PC1), hypopituitarism (HESX1,
LHX3, SOX3, PROP1), or adrenal insufficiency (DAX1) (1, 2).
Isolated hypogonadotropic hypogonadism (IHH) has been
reported due to mutations in the genes encoding the GnRH
receptor (GNRHR) or GPR54 (3–6). We hypothesized that
milder loss-of-function mutations in these genes could
present as delayed puberty and chose to address this by
studying the GNRHR gene in families in whom different
siblings had either IHH or pubertal delay.
Subjects and Methods
Subjects
Samples were obtained from eight families with delayed puberty (no
pubertal development by 14 yr in males) and three families in which
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different siblings had IHH or delayed puberty. No obvious associated
features suggestive of a more complex syndromic cause of hypogona-
dotropic hypogonadism (such as anosmia, obesity, pituitary dysfunc-
tion, or adrenal failure) were present.
Mutational analysis
After obtaining institutional review board approval and informed
consent, DNA was extracted from patients’ blood leukocytes using
standardmethods. The three coding exons and splice sites of theGNRHR
gene were PCR amplified using primer pairs and conditions described
previously (3). Sequencing reactions were performed using a Bigdye
terminator cycle sequencing kit (version 1.1; Applied Biosystems, Foster
City, CA) and MegaBACE1000 DNA sequence analyzer (Amersham
Biosciences, Buckinghamshire, UK) with Sequence Analyzer (version
3.0; Amersham Biosciences) and Sequencher (version 4.1; Genecodes
Corp., Ann Arbor, MI) software.
Hormone assays
Serum LH concentrations were measured using an immunoradio-
metric assay (North-east Thames Regional Immunoassay Services, St.
Bartholomew’s Hospital, London, UK). The within-assay coefficients of
variation (CVs) were 5.6, 3.6, 5.2, and 3.0% at serum LH concentrations
of 2.9, 7.9, 18.3 and 35.8 IU/liter and the between-assay CV values were
10.4, 3.1, and 5.4% at serum concentrations of 4.7, 34.0, and 51.7 IU/liter,
respectively. The sensitivity of the assay was 0.5 IU/liter. Serum FSH
concentrations were measured by immunoradiometric assay (North-
east Thames Regional Immunoassay Services). The within-assay CV
values were 10.7, 7.6, 7.8, and 4.3% at serum concentrations of 2.8, 5.8,
13.2, and 26.1 IU/liter and the between-assay CV values were 8.1, 4.9,
and 5.1% at serum concentrations of 2.9, 4.9, and 5.1 IU/liter, respec-
tively. The sensitivity was 0.5 IU/liter.
Gonadotropin profiling and pulse analysis
Gonadotropin profiles were performed by withdrawing blood sam-
ples from an indwelling iv catheter every 20 min for a 24-h period.
Gonadotropin pulsatility was analyzed by autocorrelation and Fourier
transform (spectral power) using Time Series Analysis software (Easy
TSA; Oxford University, Oxford, UK) with and without stationarization
(differential and mean detrending) of the data (7).
Pubertal assessment
Pubertal rating was performed using standard ratings of Marshall
and Tanner [genital stages 1–5 (G); pubic hair (P) stages 1–5; axillary hair
(A) stages 1–3] (8).
Results
A GNRHR gene mutation was identified in one of the 11
families studied, in which one brother had been diagnosed
with pubertal delay and another had IHH.
Case histories
The proband (I) was referred at 15.9 yr of age because of
delayed puberty and poor growth (Fig. 1A). He was nor-
mosmic and had no associated features of note, and past
medical and family history were unremarkable. The family
was of Asian Indian ancestry. His birth weight was 2.2 kg.
After a short course of oxandrolone, he was given 6 months
treatment with testosterone undecanoate (Sustanon, 100 mg
monthly) and reached pubertal ratings of G4, P4, A1, with 6-
and 8-cc testes by 17.1 yr of age. Puberty continued to
progress spontaneously. By 17.9 yr of age, he had ratings of
G5, P5,A2,with 12- and 15-cc testes andwas discharged from
further regular follow-up.
The younger brother (II) was referred at 11.7 yr with con-
cerns about short stature (Fig. 1B). His birth weight was 2.7
kg andhe hadmild asthma.Hewas prepubertal and received
a course of oxandralone as a growth-promoting agent. He
remained prepubertal at 14.3 yr of age and was given a short
course of testosterone undecanoate. However, at 15.5 yr of
age, he showed no spontaneous pubertal development (G3,
P3, A1, 2-cc testes bilaterally), so further investigations were
performed.
A 24-h gonadotropin profile (samples every 20 min) was
undertaken. Although spontaneous FSH and LH release was
detected throughout the day and night (Fig. 2A), time series
analysis with and without detrending showed no autocor-
relation (data not shown) and a poorly defined rapid Fourier
transform of low spectral power (Fig. 2B) (9). Spontaneous
testosterone release was virtually undetectable (Fig. 2A), but
prolonged administration of human chorionic gonadotropin
(1500 IU twice weekly) for 1 month at 16.2 yr produced a
significant testosterone response [687 ng/dl (23.7 nmol/li-
ter)] (Fig. 1D), consistent with central hypogonadism. Spon-
taneous GH release was consistent with his age and pubertal
stage, and thyroid function, prolactin, and a cortisol day
curve (27.4 g/dl at 0800 h) were normal. A hypothalamic-
pituitary magnetic resonance imaging scan and skeletal sur-
vey were unremarkable. Puberty was induced with increas-
ing doses of testosterone. Reevaluation off all treatment at
18.5 yr showed a persistently low testosterone despite go-
nadotropin responses to LHRHstimulation (Fig. 1D).Hewas
therefore continued on testosterone replacement therapy.
Both individuals were reassessed clinically in adulthood.
The proband (I) was shaving but felt he had somewhat re-
duced libido. He had detectable gonadotropins and testos-
terone toward the lower end of the normal range (Fig. 1C).
At 32 yr of age, he had reduced bone mineral density [t-
scores, 2.0 (hip) and 3.7 (lumbar spine)]. Semen analysis
showed borderline oligospermia (18 million sperm/ml, 67%
abnormal forms, 60% motility). He has recently fathered a
child.
The younger brother (II) had subnormal testosterone [191
ng/dl (6.6 nmol/liter)] 1 yr after electing to stop testosterone
replacement (Fig. 1D). This finding may reflect delayed par-
tial activation of his hypothalamic-pituitary-gonadal axis or
possible up-regulation of hypothalamic-pituitary-gonadal
activity after prior testosterone exposure. His bone mineral
density was reduced [t-scores, (1.2 hip) and 2.5 (lumbar
spine)]. He continues on testosterone replacement but has
not had semen analysis performed yet.
Mutational analysis
Direct sequencing revealed a homozygous R262Q
(CGG3CAG) mutation in both brothers. The affected argi-
nine is a highly conserved residue in the third intracellular
loop of the GnRH receptor (Fig. 2C) (10). This change has
been reported previously in a compound heterozygous state
(including Q106R/R262Q, A129D/R262Q, and R262Q/
Y284C) in several patients with IHH (3, 4, 11–15).
Discussion
Mutations in theGNRHR genewere first described in 1997,
and to date, approximately 20 different homozygous or com-
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pound heterozygous changes have been reported in patients
with idiopathic or familial forms of IHH (3, 4, 10–15). The
twomost frequentGNRHRmutations areQ106R andR262Q,
accounting for approximately half of all reported changes
(Fig. 2C) (16). Both these mutations usually occur in a com-
pound heterozygous state and have been shown to cause
partial loss of function in in vitro assays of receptor function
(17).
The Q106Rmutation causes decreased GnRH binding and
possibly misfolding (3, 17, 18). Homozygous Q106R changes
have been reported in association with milder phenotypes,
such as partial IHH in a woman and the fertile eunuch
syndrome in two males (14, 19, 20). These men had impaired
secondary virilization and 15- to 17-cc testes.However, to our
knowledge, spontaneous spermatogenesis associated with
GNRHR mutations is rare (3).
The R262Q mutation described here has been reported in
a compound heterozygous state in patients of French Cau-
casian, English-American, and Irish-American ancestry with
variable forms of IHH (3, 4, 11–15). Our finding of a ho-
mozygous R262Q mutation in an Asian Indian family sug-
gests that the R262Q change represents a mutational hot spot
rather than a founder effect. The functional consequences of
the R262Q GNRHR mutation have been studied previously
(3, 4, 17, 18). In general, this mutation does not affect GnRH
binding or trafficking of the receptor to the gonadotrope cell
surface but predominantly interferes with downstream sig-
naling through several intracellular pathways [e.g. protein
kinase C/inositol 1,4,5-triphosphate, ERK-1 (Gq/11), and
cAMP (Gs)] (Fig. 2C) (3, 4, 10, 17).
Intracellular signaling by the GNRHR is complex and re-
mains poorly understood because this single receptor must
respond to pulsatile hypothalamic GnRH stimulation to reg-
ulate the synthesis and release of both FSH and LH as well
FIG. 1. Growth charts and response to treatment for both brothers. A, The proband (I) was diagnosed with constitutional delay of growth and
puberty. B, The younger brother (II) was diagnosed with IHH. M, Maternal height; F, paternal height; FH, final height; Ox, oxandrolone; T,
testosterone undecanoate.Upward arrows indicate start of treatment and downward arrows indicate treatment discontinuation. C, Endocrine
data for the proband (I) showed testosterone values toward the lower part of the normal range (range 287–810 ng/dl; divide by 29 for nanomoles
per liter). D, Endocrine data for the younger brother at times when off testosterone treatment; a, after human chorionic gonadotropin 1500 IU
twice weekly for 1 month instead of testosterone; b, peak after LHRH stimulation; c, off testosterone 3 months; d, off testosterone 1 yr. Growth
charts reproduced courtesy of the National Center for Health Science.
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as likely having a tropic effect on the gonadotrope cell pop-
ulation. The presence of detectable but largely nonpulsatile
gonadotropin release in the younger brother with IHH stud-
ied here shows that the R262Q mutation has a more detri-
mental effect on pulsatile gonadotropin release than gonad-
otropin synthesis. Furthermore, significant amounts of LH
were released (22 IU/liter) after bolus GnRH stimulation,
consistentwith a greater effect of the R262Qmutation on FSH
regulation thanLH (17). Taken togetherwith functional stud-
ies, these findings suggest that the R262Qmutation produces
a partial block inGNRHRsignal transduction and reconfirms
the importance of pulsatile gonadotropin signaling for nor-
mal pubertal development and reproductive function to oc-
cur. This kindred also highlights the phenotypic variability
that can be seen in families with GNRHR mutations. It is
likely that modifier genes that influence reproductive de-
velopment and function could result in the variable pheno-
typic expression between these two brothers.
From the clinical perspective, this report shows that subtle
phenotypes such as apparent constitutional delay of growth
and puberty and borderline oligospermia can rarely occur
due to partial loss-of-function mutations in the GNRHR in
males. Obviously it would be inappropriate to recommend
long-term follow-up for all young adults with delayed pu-
berty because this is such a common condition, and it is
important not to medicalize or stigmatize what might be
considered a normal variant of pubertal timing. However,
emphasis should be placed on individuals seeking endocri-
nological review if they have concerns regarding potency
and fertility in the future, especially if there is an emerging
family history of IHH. Detecting those young adults with
partial forms of hypogonadotropic hypogonadism could
have implications for long-term bone health, fertility, and
psychosexual functioning, and defining the exact molecular
basis is important for focusing treatment appropriately.
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